EarlyCDT®–Lung is a simple blood test which is ordered by a Doctor to aid in the risk assessment and early detection of lung cancer. The EarlyCDT–Lung test measures a panel of seven autoantibodies to detect the presence of lung cancer.
EarlyCDT–Lung has been developed so that individuals at high risk of developing lung cancer can benefit from an increased chance that lung cancer can be detected at the earliest possible stages, when treatment can be most successful.
|Target Patients||For example:|
|Those who fall outside the USPSTF/CMS criteria for annual CT screening||A 51 year old current smoker with 32 pack year smoking history; a 60 year old ex-smoker with 30 pack year smoking history who quit 16 years ago*|
|Those who qualify for annual CT screening but are non-compliant||The blood test provides a useful option for those patients who are claustrophobic, who do not want the radiation exposure, or who live too far away from a CT scan|
|Those who are diagnosed with an indeterminate pulmonary nodule||The test can be used to identify which patients with a nodule are more likely to have lung cancer|
|*EarlyCDT-Lung has not been validated for patients <40 years of age.|
EarlyCDT–Lung offers a complementary approach to annual CT screening, seen as the gold standard in the USA for early lung cancer detection. As a simple blood test, EarlyCDT–Lung can be used when individuals are unwilling or unable to undergo lifelong, annual CT screening. It can also be used when an individual is at increased risk but does not meet the criteria for annual CT screening. In either case, a positive EarlyCDT–Lung result can be followed by suitable CTs at appropriate intervals in order to detect a lung cancer early, with the patient, physician and insurers better aware of the risk of cancer developing.
The EarlyCDT–Lung test can also be used in conjunction with diagnostic imaging techniques to further assess the risk of lung cancer being present where indeterminate lung nodules have been detected but have not been diagnosed as malignant.
This is not a genetic test for predisposition – a positive test may indicate the presence of the malignant disease.
So far, over 145,000 EarlyCDT–Lung tests have been performed commercially through over 2,000 physicians. The test has aided in the detection of numerous early stage lung cancers. It is now also available in the UK and other regions.
Electronic versions of the materials you are seeking to access are being made available on this website by Oncimmune Holdings plc (the “Company”).
These materials are not directed to nor are they intended for access by persons located or resident in the United States, Australia, Canada, South Africa, Japan or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.
None of the securities of Company discussed or referred to in the materials you are seeking to access have been registered under the US Securities Act or 1933, as amended (the “Securities Act”) and may not be offered, sold, pledged or otherwise transferred except (1) in an offshore transaction meeting the requirements of Rule 903 or Rule 904 of Regulation S under the Securities Act, (2) pursuant to an effective registration statement under the Securities Act, or (3) pursuant to an available exemption from the registration requirements of the Securities Act, in each case in accordance with all applicable securities laws.
By clicking the “SUBMIT” button below you confirm that you (1) have read and understood the information set out above, (2) agree to be bound by its terms, (3) are not located in the United States and do not have a registered address in, and are not resident or located in, Australia, Canada, South Africa or Japan and (4) are permitted under applicable law and regulation to proceed to the following parts of this website.